Duchenne Muscular Dystrophy Clinical Trial Landscape

The DMD trial landscape in 2026

Duchenne muscular dystrophy has become one of the most complex and commercially consequential rare disease settings in clinical development. Sarepta Therapeutics' approval of delandistrogene moxeparvovec (Elevidys) — the first systemic gene therapy for DMD — marked a pivotal moment, even as its regulatory path and clinical evidence base remain subjects of ongoing debate. The gene therapy landscape is now a multi-sponsor competition, with Solid Biosciences, BioMarin (fordadistrogene movaparvovec), and Pfizer (SRP-9003) all pursuing systemic AAV micro-dystrophin programs.

Simultaneously, the exon-skipping pipeline is maturing. Eteplirsen (exon 51 skip, Sarepta) paved the regulatory way; golodirsen and viltolarsen (exon 53) followed. Casimersen (exon 45) extended this strategy further. Entrada Therapeutics is developing endosomal escape technology to improve oligonucleotide delivery, with its ENTR-701 (exon 44) and ENTR-601-44 programs representing the next generation.

Key DMD program categories to monitor:

• Systemic gene therapy (AAV micro-dystrophin): Sarepta Elevidys follow-on studies, Solid Biosciences SGT-001, BioMarin fordadistrogene, Pfizer SRP-9003
• Exon skipping (antisense oligonucleotides): Next-generation exon 44, 45, 51, 53 skippers with improved delivery
• Endosomal escape technology: Entrada Therapeutics ENTR-701 and ENTR-601-44 programs
• Utrophin upregulation: Ezutromid and next-generation small molecule upregulators
• Cardiac protection: Programs specifically targeting DMD cardiomyopathy — a major cause of morbidity in older patients
• Combination approaches: Gene therapy plus exon skipping, or gene therapy plus cardiac protection

Who uses DMD trial monitoring

Rare disease BD professionals

DMD is one of the most commercially valuable rare disease settings. Sarepta built a multi-billion dollar franchise on exon-skipping antisense oligonucleotides. The gene therapy approvals — with price tags exceeding $3 million per patient — make DMD the highest per-patient revenue opportunity in neuromuscular disease. BD teams track pipeline entries to identify early-stage assets for in-licensing and assess competitive threats to existing franchise assets.

Gene therapy investors

Analysts tracking gene therapy use DMD trial registrations as indicators of program maturity and competitive positioning. The question of whether any follow-on micro-dystrophin program (BioMarin, Solid Biosciences) can demonstrate superiority to Elevidys on functional outcomes — and whether the accelerated approval standard will hold for the category — is the central investment thesis question in DMD gene therapy.

Patient advocacy-engaged companies

Parent Project Muscular Dystrophy and Cure Duchenne have unusually active roles in DMD clinical development. Companies developing in DMD must maintain awareness of both competitor programs and advocacy preferences, particularly around exon-specific patient subpopulations who are eligible for different treatments.

Current DMD trial activity (as of early 2026)

Based on ClinicalTrials.gov data updated daily by DataLookout:

BioMarin's fordadistrogene movaparvovec (BMN 307) had an initial clinical hold lifted and a Phase 3 study is progressing. Unlike Elevidys which uses a truncated micro-dystrophin, fordadistrogene targets a different construct. The head-to-head competitive question — which construct produces superior functional dystrophin and functional outcomes — remains to be answered in Phase 3.

Entrada Therapeutics' Endosomal Escape Vehicle (EEV) technology addresses the fundamental delivery challenge of oligonucleotide therapies: getting the ASO into muscle cells efficiently. ENTR-701 (exon 44 skipping) and ENTR-601-44 represent next-generation exon skippers that, if the technology works, could obsolete earlier-generation APC-based exon skippers by achieving therapeutic tissue concentrations at much lower doses.

Frequently asked questions